Latest Retail News

Challenger Limited has reported a robust first half of FY25, with a 12% increase in normalized NPAT and significant strides in annuity sales and technology modernization, positioning the company for sustained growth.

Challenger Limited posted a robust first half of FY25, with normalised net profit after tax rising 12% to $225 million, underpinned by strong Life and Funds Management segments despite softer annuity sales. The company maintains a confident outlook for FY25, forecasting further profit growth.

Challenger Limited reported a robust 12% increase in normalized NPAT to $225 million for 1H25, underpinned by strong earnings, dividend growth, and strategic investments in technology and distribution channels.

Challenger Limited reported a robust first half of FY25, delivering a 12% rise in normalised net profit after tax and record annuity sales, underpinned by strategic technology investments and longer tenor products.

Challenger Limited reported a robust 28% increase in statutory net profit after tax to $72 million for 1H25, alongside a 12% rise in normalised net profit and a higher interim dividend. Despite a 12% decline in total life sales, the company’s assets under management grew 12% to $131 billion, reflecting strong operational momentum.

Turners Automotive Group has raised its FY25 profit guidance to at least NZ$53 million, marking its fifth consecutive record profit despite challenging economic conditions.

Judo Capital Holdings Limited has released its Basel III Pillar 3 report for the half year ended December 31, 2024, revealing a robust capital position and detailed credit risk exposures that exceed regulatory transparency requirements.

Judo Bank has reported a robust half-year performance with a 70% jump in statutory net profit, driven by strong loan growth and improved margins, while reaffirming its FY25 profit guidance.

Icetana Limited has successfully closed its renounceable pro rata entitlement offer, raising $629,422 through new share issuance, with convertible notes poised to convert into shares shortly.

Simonds Group reported a 5.6% revenue decline for the half year ended December 2024 but achieved a 12% rise in EBITDA, driven by higher margin projects and cost control. The company also announced a strategic acquisition to expand its footprint.

PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.

PYC Therapeutics is set to raise up to $146 million through a pro-rata entitlement offer, aiming to accelerate its RNA-based drug candidates targeting major unmet medical needs. Major shareholder support and underwriting commitments underpin the capital raise.